NCT05243524 — Platinum-resistant Epithelial Ovarian Cancer trial site landscape

Public-registry site landscape for NCT05243524, a Platinum-resistant Epithelial Ovarian Cancer study sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.). All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT05243524 (registry record)
Sponsor	ImmunoVaccine Technologies, Inc. (IMV Inc.)
Condition(s)	Platinum-resistant Epithelial Ovarian Cancer
Phase	PHASE2
Listed sites	6
Site countries	United States, Canada, Puerto Rico

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT05243524 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →
Launch offer through July 31: first full site unlock free — one per company.